Immunotherapy in biliary tract cancers: Current evidence and future perspectives

Area of Science:

• Oncology
• Immunology

Background:

• Bile duct tumors, including intrahepatic, extrahepatic, and gallbladder tumors, are aggressive with poor survival rates in advanced stages.
• Chemotherapy remains the primary treatment for advanced disease, but outcomes are often limited.

Purpose of the Study:

• To explore the significance of immunotherapy, specifically immune checkpoint inhibitors (ICI), for advanced bile duct tumors.
• To review recent advancements and strategies for enhancing ICI efficacy in this patient population.

Main Methods:

• Review of recent Food and Drug Administration approvals for ICI based on biomarkers like microsatellite instability-high and tumor mutation burden-high.
• Analysis of drug combination strategies aimed at improving ICI efficacy in advanced bile duct tumors.

Main Results:

• ICI approvals for biomarker-defined tumors represent a significant step in treating advanced bile duct cancers.
• Isolated ICI use in later treatment lines shows limited response.
• Combination strategies are demonstrating encouraging results in enhancing ICI efficacy.

Conclusions:

• Immunotherapy, particularly ICI, is a critical area of research for improving outcomes in advanced bile duct tumors.
• Combination therapies hold significant promise for enhancing treatment efficacy and patient survival.